Comparative Pharmacology
Head-to-head clinical analysis: TRULICITY versus WEGOVY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRULICITY versus WEGOVY.
TRULICITY vs WEGOVY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucagon-like peptide-1 (GLP-1) receptor agonist. Increases glucose-dependent insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Semaglutide, a GLP-1 receptor agonist, increases insulin secretion, decreases glucagon secretion, delays gastric emptying, and reduces appetite via central GLP-1 receptor activation.
1.5 mg subcutaneously once weekly, with or without food.
Subcutaneous injection 0.25 mg once weekly for 4 weeks, then increase to 0.5 mg once weekly for 4 weeks, then 1 mg once weekly for 4 weeks, then 1.7 mg once weekly for 4 weeks, then maintenance 2.4 mg once weekly.
None Documented
None Documented
Terminal elimination half-life approximately 5 days (112–120 hours) after subcutaneous administration, supporting once-weekly dosing.
Terminal elimination half-life is approximately 1 week (6–8 days), supporting once-weekly subcutaneous dosing.
Renal: negligible (intact peptide not excreted in urine); Biliary/fecal: peptide backbone catabolized via proteolysis, with amino acids recycled; no biliary excretion of intact drug.
Primarily renal; approximately 97% of the dose is excreted unchanged in urine, with less than 3% in feces via biliary excretion.
Category C
Category C
GLP-1 Receptor Agonist
GLP-1 Receptor Agonist